TUEs and the Athlete With Real Hypogonadism
Why a Genuinely Deficient Athlete Still Usually Cannot Use Testosterone in Sport
Evidence grade 5 of 5, Settled. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- Not an FDA matter; governed by the WADA Code and ISTUE
- WADA
- Prohibited at all times (S1 Anabolic Agent); TUE rarely granted
Reference only. Not medical advice.
What can go wrong
An athlete who takes testosterone without a valid TUE commits an anti-doping rule violation with multi-year ban exposure, even with a real clinical diagnosis. A physician's TRT prescription provides no anti-doping protection. Athletes must consult their sport's anti-doping organization before any testosterone therapy.
This is something to take to a clinician. The Atlas can tell you what is known about tues and the athlete with real hypogonadism in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
This entry focuses on the hardest case in the WADA Therapeutic Use Exemption system: the athlete with genuine hypogonadism. The International Standard for TUEs (ISTUE) requires, among other criteria, that the therapy produce no additional performance enhancement beyond a return to normal health. Because exogenous testosterone is inherently ergogenic and replacement targets are hard to pin to an individual's true physiologic baseline, even organically hypogonadal athletes struggle to obtain a competition TUE. Functional/age-related low testosterone, the marketplace's main target, essentially never qualifies, and prior anabolic-steroid use disqualifies outright.
Even an athlete with documented testicular failure faces a TUE bar that testosterone almost cannot clear.
What people take it for
What it is taken for. Approval, where it exists, covers only some of these.
How it works
An ISTUE-compliant TUE must show: significant health impairment without the drug; no net performance benefit beyond restoring normal health; no permitted alternative; and that the need did not arise from prior prohibited-substance use. Testosterone fails the second criterion easily because dosing to a 'normal' level in an athlete is both ergogenic and difficult to calibrate to that athlete's true endogenous baseline, a problem compounded by the wide normal range and by the fact that supraphysiological excursions raise performance. Panels therefore apply intense scrutiny and frequently decline.
The optimization narrative collides head-on with sport
The DTC marketplace sells testosterone to men with low-normal or age-related decline as 'optimization.' Under WADA logic that population is functional, not organic, and would not qualify for a TUE; worse, an athlete who starts marketplace TRT can render himself ineligible and may trip Athlete Biological Passport flags. Even the sympathetic case, a younger athlete with verified testicular or pituitary failure, faces the 'no added enhancement' bar, because restoring testosterone in an athletic body confers competitive benefit by design. This is why anti-doping authorities treat testosterone TUEs as among the most restrictive categories.
What people get wrong
Often saidA documented diagnosis guarantees a TUE
ActuallyNo, even organic hypogonadism must clear the 'no additional performance enhancement' criterion, which testosterone rarely satisfies.
Often saidAge-related low T qualifies an athlete for a TUE
ActuallyFunctional/age-related decline, the optimization market's target, generally does not qualify.
Often saidA doctor's prescription protects an athlete
ActuallyOnly a valid TUE does; a prescription alone is an anti-doping rule violation if the substance is prohibited.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
At a glance
- Standard
- International Standard for TUEs (ISTUE)
- Core barrier
- 'No additional performance enhancement beyond return to normal health'
- Qualifying condition
- Generally only documented organic hypogonadism (structural/genetic)
- Disqualifier
- Prior non-therapeutic anabolic-steroid use
- Functional/age-related low T
- Generally not eligible
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about TUEs and the Athlete With Real Hypogonadism. A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
International Standard for TUEs (ISTUE)ongoing
Sets the four-criterion test; the 'no additional enhancement' prong is decisive for testosterone
WADA Prohibited List S1annual
Bans testosterone and its esters at all times
Hypogonadism case reviewsvarious
Document the rarity of granted testosterone TUEs outside organic deficiency